Chemoinformaics analysis of Terbutylazine-2-hydroxy
Molecular Weight | 211.269 | nRot | 3 |
Heavy Atom Molecular Weight | 194.133 | nRig | 9 |
Exact Molecular Weight | 211.143 | nRing | 1 |
Solubility: LogS | -2.109 | nHRing | 1 |
Solubility: LogP | 0.819 | No. of Aliphatic Rings | 0 |
Acid Count | 0 | No. of Aromatic Rings | 1 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 32 | No. of Aliphatic Hetero Cycles | 0 |
No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 17 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 5 | No. of Arom Atom | 6 |
No. of Oxygen atom | 1 | No. of Arom Bond | 6 |
nHA | 5 | APOL | 32.6675 |
nHD | 3 | BPOL | 21.9125 |
QED | 0.582 |
Synth | 4.047 |
Natural Product Likeliness | -0.508 |
NR-PPAR-gamma | 0.001 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Accepted |
Pgp-inh | 0 |
Pgp-sub | 0.871 |
HIA | 1 |
CACO-2 | -4.217 |
MDCK | 0.000107324 |
BBB | 0.855 |
PPB | 0.142401 |
VDSS | 0.994 |
FU | 0.668785 |
CYP1A2-inh | 0.018 |
CYP1A2-sub | 0.966 |
CYP2c19-inh | 0.05 |
CYP2c19-sub | 0.039 |
CYP2c9-inh | 0.001 |
CYP2c9-sub | 0.017 |
CYP2d6-inh | 0 |
CYP2d6-sub | 0 |
CYP3a4-inh | 0.023 |
CYP3a4-sub | 0.939 |
CL | 6.601 |
T12 | 0.926 |
hERG | 0.641 |
Ames | 0.101 |
ROA | 0.359 |
SkinSen | 0.945 |
Carcinogencity | 0.952 |
EI | 0.246 |
Respiratory | 0.977 |
NR-Aromatase | 0.001 |
Antiviral | No |
Prediction | 0.870154 |